April 5, 2017
Heptares trigers milestone payment from AstraZeneca
Sosei Group Corporation’s subsidiary Heptares Therapeutics got milestone payment from AstraZeneca for working together on an immuno-oncology project.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 5, 2017
Abzena raises £25 M to boost its growth
Abzena, a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, will initiate a placing to raise approximately £25 million to expand further its service offering, capacity and capabilities.
April 5, 2017
Sanofi’s partner JHL Biotech accepted for clinical trial in China
JHL Biotech said Wednesday its Clinical Trial Application (CTA) for use of its first product in pipleine, JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by the China Food and Drug Administration (CFDA).
April 5, 2017
BD buys Israel’s CME
BD (Becton, Dickinson and Company), a medical technology company, has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems manufacturer.
April 5, 2017
Radiopharmaceuticals market could double up in 4 years
According to the report, the global market radiopharmaceuticals were valued at nearly $5.1 billion and $5.7 billion in 2014 and 2015, respectively.
April 4, 2017
FDA will look into Janssen’s sNDA for ibrutinib
The U.S. FDA will review a supplemental New Drug Application for Janssen’s Imbruvica for chronic graft-versus-host-disease after failed certain therapies.
April 4, 2017
Cannabics Pharmaceuticals gets final report of its research on antitumor properties of cannabinoids in Israel
Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer.
April 4, 2017
Creso Pharma welcomes new COO
Creso Pharma has appointed pharmaceutical and biotech industry professional David Russell as its Chief Operating Officer.
April 4, 2017
Galapagos in three new Phase 2 studies with filgotinib
Galapagos NV announced on Tuesday three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren`s syndrome, ankylosing spondylitis, and psoriatic arthritis.
April 4, 2017
Verona Pharma doses first patients in UK testing its cystic fibrosis candidate
Verona Pharma has dosed the first patient in a phase 2a test of its candidate RPL554 for cystic fibrosis, the most common fatal inherited disease in the United States and Europe.